CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

18th Congress of the International Headache Society

IHC 2017 Scientific Sessions News

IHC 2017: New analyses add more supporting evidence for CGRP inhibitors in migraine prophylaxis

Presentations during IHC 2017, the 18th Congress of the International Headache Society, held recently in Vancouver, Canada, underscore the efficacy and safety of CGRP inhibitors in both episodic and chronic migraine.

Rapid and sustained efficacy of eptinezumab in chronic migraine

There were greater reductions compared to placebo in both the proportion of patients experiencing a migraine and the number of migraine hours experienced in the 24 hours after a single intravenous infusion of eptinezumab.

Read the full report here »

STRIVE study shows erenumab is effective in episodic migraine even when previous prevention has failed

Treatment with erenumab reduces monthly migraine days in patients with episodic migraine who have not responded to prior preventive treatments. A safety study also shows no effect on treadmill testing in patients with stable angina

Read the full report to here »

Positive long-term safety data for self-administered galcanezumab

Galcanezumab 120 mg and 240 mg once monthly is efficacious and well tolerated when administered by patients themselves for up to 12 months, according to a randomised, open-label phase 3 study.

Read the full report here »

HALO studies highlight efficacy and safety of fremanezumab in chronic and episodic migraine

Fremanezumab achieved statistically significant and clinically meaningful results for all 25 primary and secondary analyses in both monthly and quarterly dosing regimens investigated in the phase 3 HALO studies in chronic and episodic migraine.

Read the full report here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2017. Please click here to unsubscribe from future mailings.